Trial · NCT02834052
Adverse events87
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 87
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Abdominal Distention | Gastrointestinal disorders | Phase 1: Poly-ICLC: 1mg | 1 | 8 | 1 |
| serious | Abdominal Distention | Gastrointestinal disorders | Phase 1: Poly-ICLC: 2mg | 0 | 10 | 0 |
| serious | Abdominal Distention | Gastrointestinal disorders | Phase 2: Poly-ICLC: 2mg | 1 | 24 | 1 |
| serious | Dyspnea | Respiratory, thoracic and mediastinal disorders | Phase 1: Poly-ICLC: 1mg | 3 | 8 | 3 |
| serious | Dyspnea | Respiratory, thoracic and mediastinal disorders | Phase 1: Poly-ICLC: 2mg | 1 | 10 | 1 |
| serious | Dyspnea | Respiratory, thoracic and mediastinal disorders | Phase 2: Poly-ICLC: 2mg | 2 | 24 | 2 |
| serious | Small Bowel Obstruction | Gastrointestinal disorders | Phase 1: Poly-ICLC: 1mg | 1 | 8 | 1 |
| serious | Small Bowel Obstruction | Gastrointestinal disorders | Phase 1: Poly-ICLC: 2mg | 0 | 10 | 0 |
| serious | Small Bowel Obstruction | Gastrointestinal disorders | Phase 2: Poly-ICLC: 2mg | 0 | 24 | 0 |
| serious | Leukocytosis | Blood and lymphatic system disorders | Phase 1: Poly-ICLC: 1mg | 0 | 8 | 0 |
| serious | Leukocytosis | Blood and lymphatic system disorders | Phase 1: Poly-ICLC: 2mg | 1 | 10 | 1 |
| serious | Leukocytosis | Blood and lymphatic system disorders | Phase 2: Poly-ICLC: 2mg | 1 | 24 | 1 |
| serious | Death | General disorders | Phase 1: Poly-ICLC: 1mg | 1 | 8 | 1 |
| serious | Death | General disorders | Phase 1: Poly-ICLC: 2mg | 1 | 10 | 1 |
| serious | Death | General disorders | Phase 2: Poly-ICLC: 2mg | 2 | 24 | 2 |
| serious | Sepsis | Infections and infestations | Phase 1: Poly-ICLC: 1mg | 0 | 8 | 0 |
| serious | Sepsis | Infections and infestations | Phase 1: Poly-ICLC: 2mg | 0 | 10 | 0 |
| serious | Sepsis | Infections and infestations | Phase 2: Poly-ICLC: 2mg | 1 | 24 | 1 |
| serious | Intracranial Hemorrhage | Nervous system disorders | Phase 1: Poly-ICLC: 1mg | 0 | 8 | 0 |
| serious | Intracranial Hemorrhage | Nervous system disorders | Phase 1: Poly-ICLC: 2mg | 0 | 10 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02834052/events